Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Relypsa Inc (NASDAQ: RLYP) shares are up more than 15 percent on Friday afternoon after unconfirmed reports that Merck & Co., Inc. (NYSE: MRK) could make a bid for the $1.07 billion bio therapeutic company. A source familiar with the matter told Benzinga Merck is not involved with a bid, but that 3 to 4 companies are evaluating Relypsa.
According to the source, the evaluation process is in its early stages and no developments are expected until at least 2016.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Sanofi Seen As 'Natural Buyer'
In a conversation with Benzinga, Wedbush analyst Liana Moussatos said Sanofi SA (ADR) (NYSE: SNY) is a "natural buyer" of Relypsa. In August of this year, Relypsa entered into a two-year detailing and distribution agreement with Sanofi for its hyperkalemia treatment, Veltassa, which received FDA approval in late October.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Veltassa is expected to be available to doctors and patients in January 2016 and is the first new treatment for Hyperkalemia in over 50 years.
Billion-Dollar Potential
In a note published shortly after the drug gained FDA approval, Moussatos said she expected Veltassa to have a successful launch to start the New Year, eventually resulting in peak annual sales of more than $1 billion in the U.S. alone. The analyst projected MAA submission would be made in the first half of 2015, followed by a potential launch in the European Union by the middle of 2017.
Moussatos' projections show the drug could reach more than 3 million patients facing moderate to severe hyperkalemia and over 13 million suffering from a milder case of the condition.
The analyst holds a $75 12-month price target on Relypsa. Shares currently trade near the $26 mark.
Jake Mann contributed to this report.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.